European urology oncology最新文献

{"title":"Management of Small Testicular Masses: A Delphi Consensus Study","authors":"Karl H. Pang ,&nbsp;Giuseppe Fallara ,&nbsp;João Lobo ,&nbsp;Hussain M. Alnajjar ,&nbsp;Vijay Sangar ,&nbsp;Conrad von Stempel ,&nbsp;Dean Y. Huang ,&nbsp;Arie Parnham ,&nbsp;Walter Cazzaniga ,&nbsp;Francesco Giganti ,&nbsp;Aiman Haider ,&nbsp;Ashwin Sachdeva ,&nbsp;Maarten Albersen ,&nbsp;Costi Alifrangis ,&nbsp;Marco Bandini ,&nbsp;Fabio Castiglione ,&nbsp;Hielke-Martijn De Vries ,&nbsp;Christian Fankhauser ,&nbsp;Daniel Heffernan Ho ,&nbsp;David Nicol ,&nbsp;Asif Muneer","doi":"10.1016/j.euo.2024.10.010","DOIUrl":"10.1016/j.euo.2024.10.010","url":null,"abstract":"<div><h3>Background and objective</h3><div>The majority of small testicular masses (STMs) are benign and therefore radical orchidectomy (RO) may represent overtreatment. In appropriately selected patients, surveillance or testis-sparing surgery (TSS) is an alternative option to preserve testicular function. Since there are no clear guidelines, we aimed to develop consensus recommendations on the management of STMs.</div></div><div><h3>Methods</h3><div>A four-round Delphi study was conducted by 24 experts representing multiple subspecialties to reach consensus. Consensus was defined as ≥75% of the participants scoring within the same 3-point grouping (1–3, disagree; 4–6, uncertain; 7–9, agree.). The first two rounds were survey based, the third round was an online meeting to discuss uncertainties from the first two rounds, and the fourth round was a review of the final consensus statements from rounds 1–3.</div></div><div><h3>Key findings and limitations</h3><div>The initial survey consisted of 126 statements. Following the four rounds of assessment, a list of 96 statements were produced, which focused on clinical and biochemical assessment, colour Doppler ultrasound (CDUS) characteristics, and management options including surveillance, RO, and TSS. Management should be personalised according to risk factors for testicular cancer, fertility status, uni- or bilateral tumours, status of the contralateral testis, and CDUS characteristics, with solid lesions displaying vascularity and hypoechogenicity being more suspicious for malignancy. The consensus statements are prone to a bias, and some may not reflect robust, randomised evidence.</div></div><div><h3>Conclusions and clinical implications</h3><div>The expert panel has produced consensus recommendations on the management of STMs, and TSS should be considered in patients with an STM. The recommendations could aid in the dissemination of best practice.</div></div><div><h3>Patient summary</h3><div>There are no clear guidelines on the management of small testicular masses. Excising the whole testicle (radical orchidectomy) with a small or an indeterminate mass may affect fertility and hormonal function. A panel of experts was formed, and consensus recommendations were developed on how to deal with small and indeterminate testicular masses, which include surveillance or testis-sparing surgery.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 152-163"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-related Quality of Life Assessment in Renal Cell Cancer: A Scoping Review","authors":"Franziska Gross ,&nbsp;Ida Marie Lind Rasmussen ,&nbsp;Elisabeth Grov Beisland ,&nbsp;Gøril Tvedten Jorem ,&nbsp;Christian Beisland ,&nbsp;Helle Pappot ,&nbsp;Juan Ignacio Arraras ,&nbsp;Madeline Pe ,&nbsp;Bernhard Holzner ,&nbsp;Lisa M. Wintner ,&nbsp;EORTC Quality of Life Group","doi":"10.1016/j.euo.2024.09.007","DOIUrl":"10.1016/j.euo.2024.09.007","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background and objective&lt;/h3&gt;&lt;div&gt;In oncology, patient-reported outcome measures (PROMs) capturing health-related quality of life (HRQOL) play an increasing role in clinical trials, drug approval, and policy making. This scoping review aimed to identify and elaborate on HRQOL-focussed PROMs used in renal cell cancer (RCC) clinical trials.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;MEDLINE, Web of Science, PsychINFO, Academic Search Elite, CINAHL, Embase, and the Cochrane Library were searched systematically for original peer-reviewed articles on clinical trials including RCC patients and using PROMs, published between 1950 and 2023. Prespecified trial characteristics and information on the PROMs used were extracted. Frequencies and proportions of categorical data, and ranges and medians of continuous variables were calculated.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Key findings and limitations&lt;/h3&gt;&lt;div&gt;Of the 48 unique studies included, the majority followed a randomised controlled design (34, 71%) and evaluated systemic treatments (38, 79%). The trials used 27 different PROMs (max = 6, median = 2), of which only 4 (15%) were developed specifically for kidney cancer patients. Of the trials, 46% did not use any RCC-specific PROM. European Quality of Life—5 Dimensions (EQ-5D), European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30), Functional Assessment of Cancer Therapy Kidney Symptom Index (FKSI) —15/19-item version, FKSI—Disease Related Symptoms, and Functional Assessment of Cancer Therapy—General (FACT-G) were the most frequently used questionnaires, with pain, ability to work, fatigue, worry, and sleep quality being the most commonly assessed issues.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions and clinical implications&lt;/h3&gt;&lt;div&gt;A variety of PROMs are used in RCC patients, hindering interpretability across trials. The PROMs used differ in terms of both the domains assessed and how the issues are translated into questionnaire items. Though RCC-specific PROMs exist, these have flaws in terms of relevance to patients. To answer predefined relevant HRQOL research questions, revised RCC-specific PROMs and standardisation of their integration into clinical trials are warranted.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Patient summary&lt;/h3&gt;&lt;div&gt;Researchers are more and more interested in the health-related quality of life of kidney cancer patients and use questionnaires to measure it. This review shows that there are many different health-related quality of life questionnaires that are used in different combinations in clinical trials for kidney cancer patients. This makes it very difficult to compare these study results and draw reliable conclusions for the actual clinical treatment. It was even found that some of the questionnaires used do not capture things that patients actually consider important (eg, emotional issues such as dealing with thoughts about cancer and depression). Therefore, more work needs to be done to develop questionnaires t","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 201-212"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial","authors":"Loic Ah-Thiane ,&nbsp;Loic Campion ,&nbsp;Nedjla Allouache ,&nbsp;Emmanuel Meyer ,&nbsp;Pascal Pommier ,&nbsp;Nathalie Mesgouez-Nebout ,&nbsp;Anne-Agathe Serre ,&nbsp;Gilles Créhange ,&nbsp;Valentine Guimas ,&nbsp;Emmanuel Rio ,&nbsp;Paul Sargos ,&nbsp;Sylvain Ladoire ,&nbsp;Céline Mahier Ait Oukhatar ,&nbsp;Stéphane Supiot","doi":"10.1016/j.euo.2024.04.014","DOIUrl":"10.1016/j.euo.2024.04.014","url":null,"abstract":"<div><h3>Background</h3><div>The relevance of next-generation hormone therapies and circulating tumor cells (CTCs) are not elucidated in biochemical recurrence after prostatectomy.</div></div><div><h3>Objective</h3><div>To evaluate the combination of abiraterone acetate plus prednisone (AAP), prostate bed radiotherapy (PBRT), and goserelin in biochemically relapsing men after prostatectomy, and to investigate the utility of CTCs.</div></div><div><h3>Design, setting, and participants</h3><div>In this single-arm multicenter phase 2 trial, 46 biochemically relapsing men were enrolled between December 2012 and January 2019. The median follow-up was 47 mo.</div></div><div><h3>Intervention</h3><div>All patients received AAP 1000 mg daily (but 750 mg during PBRT), salvage PBRT, and goserelin.</div></div><div><h3>Outcome measurements and statistical analysis</h3><div>The primary outcome was 3-yr biochemical recurrence-free survival (bRFS) when prostate-specific antigen (PSA) levels were ≥0.2 ng/ml. The secondary outcomes included alternative bRFS (alt-bRFS) when PSA levels were ≥0.5 ng/ml and safety assessment. CTC count was assessed.</div></div><div><h3>Results and limitations</h3><div>The 3-yr bRFS and alt-bRFS were 81.5% (95% confidence interval or CI [66.4–90.3%]) and 95.6% (95% CI [83.5-98.9%]), respectively. The most common acute radiotherapy-related adverse effect (AE; all grades was pollakiuria (41.3%). The most common late AE (all grades) was urinary incontinence (15.2%). Grade 3-4 acute or late radiotherapy-related AEs were scarce. Most frequent AEs nonrelated to radiotherapy were hot flashes (76%), hypertension (63%), and hepatic cytolysis (50%, of which 20% were of grades 3-4). Of the patients, 11% had a CTC count of ≥5, which was correlated with poorer bRFS (<em>p</em> = 0.042) and alt-bRFS (<em>p</em> = 0.008). The association between CTC count and higher rates of relapse was independent of the baseline PSA level and PSA doubling time (<em>p</em> = 0.42 and <em>p</em> = 0.09, respectively). This study was nonrandomized with a limited number of patients, and few clinical events were reported.</div></div><div><h3>Conclusions</h3><div>Adding AAP to salvage radiation therapy and goserelin resulted in high bRFS and alt-bRFS. AEs remained manageable, although a close liver surveillance is advised. CTC count appears as a promising biomarker for prognosis and predicting response to treatment.</div></div><div><h3>Patient summary</h3><div>Our study was a phase 2 clinical trial that exhibited the efficacy and tolerance of a novel androgen-receptor targeting agent (abiraterone acetate plus prednisone) in patients with prostate cancer who experienced rising prostate-specific antigen after radical prostatectomy, in combination with prostate bed radiotherapy. The results also indicated the feasibility and potential value of circulating tumor cell detection, which constitutes a possible advance in managing prostate cancers.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 38-46"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140907917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Cost-effectiveness of Artificial Intelligence–assisted Pathology for Prostate Cancer Diagnosis in Sweden: A Microsimulation Study","authors":"Xiaoyang Du ,&nbsp;Shuang Hao ,&nbsp;Henrik Olsson ,&nbsp;Kimmo Kartasalo ,&nbsp;Nita Mulliqi ,&nbsp;Balram Rai ,&nbsp;Dominik Menges ,&nbsp;Emelie Heintz ,&nbsp;Lars Egevad ,&nbsp;Martin Eklund ,&nbsp;Mark Clements","doi":"10.1016/j.euo.2024.05.004","DOIUrl":"10.1016/j.euo.2024.05.004","url":null,"abstract":"<div><h3>Background and objective</h3><div>Image-based artificial intelligence (AI) methods have shown high accuracy in prostate cancer (PCa) detection. Their impact on patient outcomes and cost effectiveness in comparison to human pathologists remains unknown. Our aim was to evaluate the effectiveness and cost-effectiveness of AI-assisted pathology for PCa diagnosis in Sweden.</div></div><div><h3>Methods</h3><div>We modeled quadrennial prostate-specific antigen (PSA) screening for men between the ages of 50 and 74 yr over a lifetime horizon using a health care perspective. Men with PSA ≥3 ng/ml were referred for standard biopsy (SBx), for which cores were either examined via AI followed by a pathologist for AI-labeled positive cores, or a pathologist alone. The AI performance characteristics were estimated using an internal STHLM3 validation data set. Outcome measures included the number of tests, PCa incidence and mortality, overdiagnosis, quality-adjusted life years (QALYs), and the potential reduction in pathologist-evaluated biopsy cores if AI were used. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio.</div></div><div><h3>Key findings and limitations</h3><div>In comparison to a pathologist alone, the AI-assisted workflow increased the number of PSA tests, SBx procedures, and PCa deaths by ≤0.03%, and slightly reduced PCa incidence and overdiagnosis. AI would reduce the proportion of biopsy cores evaluated by a pathologist by 80%. At a cost of €10 per case, the AI-assisted workflow would cost less and result in &lt;0.001% lower QALYs in comparison to a pathologist alone. The results were sensitive to the AI cost.</div></div><div><h3>Conclusions and clinical implications</h3><div>According to our model, AI-assisted pathology would significantly decrease the workload of pathologists, would not affect patient quality of life, and would yield cost savings in Sweden when compared to a human pathologist alone.</div></div><div><h3>Patient summary</h3><div>We compared outcomes for prostate cancer patients and relevant costs for two methods of assessing prostate biopsies in Sweden: (1) artificial intelligence (AI) technology and review of positive biopsies by a human pathologist; and (2) a human pathologist alone for all biopsies. We found that addition of AI would reduce the pathology workload and save money, and would not affect patient outcomes when compared to a human pathologist alone. The results suggest that adding AI to prostate pathology in Sweden would save costs.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 80-86"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141093309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model","authors":"Julien Anract ,&nbsp;Clément Klein ,&nbsp;Ugo Pinar ,&nbsp;Morgan Rouprêt ,&nbsp;Nicolas Barry Delongchamps ,&nbsp;Grégoire Robert","doi":"10.1016/j.euo.2024.08.009","DOIUrl":"10.1016/j.euo.2024.08.009","url":null,"abstract":"<div><h3>Background and objective</h3><div>Histopathological examination of surgical specimens for benign prostatic hyperplasia (BPH) can detect incidental prostate cancer (iPCa). The aim of our study was to develop a predictive model for iPCa diagnosis for patients for whom BPH surgery is being considered.</div></div><div><h3>Methods</h3><div>We conducted a retrospective analysis of medical files for patients who underwent BPH surgery in three academic centers between 2012 and 2022. Patients diagnosed with PCa before surgery were excluded. We calculated the global iPCa rate, and the clinically significant iPCa rate (grade group ≥2). Univariate and multivariable regression models were used to assess factors predictive of iPCa. The area under the receiver operating characteristic curve (AUC) was compared for each risk factor and for the global model. We used χ² automated interaction detection (CHAID) for decision tree analysis.</div></div><div><h3>Key findings and limitations</h3><div>We included 2452 patients in the analysis, of whom 247 (10.0%) had iPCa, which was clinically significant in 49/247 cases (20.2%). Multivariable analysis revealed that age and prostate-specific antigen density (PSAD) were independent predictive factors for iPCa diagnosis. The AUC for a model including age and PSAD was 0.65. CHAID analysis revealed that patients with PSAD &gt;0.1 ng/ml/cm³ had an iPCa risk of 23.4% (χ² = 52.6; <em>p</em> &lt; 0.001). For those patients, age &gt;72 yr increased the iPCa risk to 35.4% (χ² = 11.1, <em>p</em> = 0.008). Our study is mainly limited by its retrospective design.</div></div><div><h3>Conclusions and clinical implications</h3><div>Age and PSAD were independent risk factors for iPCa diagnosis. The combination of age &gt;72 yr and PSAD &gt;0.1 ng/ml/cm³ was associated with an iPCa rate of 35.4%.</div></div><div><h3>Patient summary</h3><div>We performed a study to find predictors of prostate cancer for patients undergoing surgery for benign enlargement of the prostate. Our model can identify patients at risk, and diagnose their cancer before surgery. This could avoid unnecessary or harmful procedures.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 145-151"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to Refine Prostate Cancer Epidemiology: Defining New Endpoints for Effective Screening and Causal Epidemiological Studies","authors":"Olivier Cussenot ,&nbsp;Morgan Rouprêt ,&nbsp;Shahrokh F. Shariat","doi":"10.1016/j.euo.2024.12.004","DOIUrl":"10.1016/j.euo.2024.12.004","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 7-8"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142893087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis","authors":"Mehul Gupta ,&nbsp;Connor Wells ,&nbsp;Meredith M. Regan ,&nbsp;Wanling Xie ,&nbsp;Vishal Navani ,&nbsp;Renee Maria Saliby ,&nbsp;Naveen S. Basappa ,&nbsp;Frede Donskov ,&nbsp;Takeshi Yuasa ,&nbsp;Kosuke Takemura ,&nbsp;Christian K. Kollmannsberger ,&nbsp;Megan Crumbaker ,&nbsp;Aly-Khan A. Lalani ,&nbsp;Thomas Powles ,&nbsp;Hedyeh Ebrahimi ,&nbsp;Rana R. McKay ,&nbsp;Jae-Lyun Lee ,&nbsp;Ravindran Kanesvaran ,&nbsp;Toni K. Choueiri ,&nbsp;Daniel Y.C. Heng","doi":"10.1016/j.euo.2024.12.011","DOIUrl":"10.1016/j.euo.2024.12.011","url":null,"abstract":"<div><h3>Background and objective</h3><div>Patients receiving immune checkpoint blockade (ICB) therapy may experience periods of prolonged disease control without a need for systemic therapy. Treatment-free survival (TFS) is an important measure for this period, but no data are available for patients with metastatic renal cell carcinoma (mRCC) starting first-line agents. Our aim was to analyze TFS outcomes for patients with mRCC starting first-line therapy.</div></div><div><h3>Methods</h3><div>We analyzed data for patients with mRCC starting first-line systemic therapy with VEGFR-targeted monotherapy, an ICB + VEGFR combination, or an ICB doublet from February 1, 2014 to February 1, 2023 from the multicenter International Metastatic RCC Database Consortium (IMDC) database. We estimated 36-mo TFS as the difference in restricted mean survival time between (1) the time to first-line therapy discontinuation and (2) the time to subsequent systemic therapy initiation.</div></div><div><h3>Key findings and limitations</h3><div>The study population included 3758 patients receiving either first-line VEGFR monotherapy (<em>n</em> = 2635), an ICB + VEGFR combination (<em>n</em> = 354), or doublet ICB (<em>n</em> = 769) were included. For the IMDC favorable-risk cohort, the 36-mo TFS estimate was 3.1 mo (95% confidence interval [CI] 1.5–4.6) for the VEGFR monotherapy group and 3.7 mo (95% CI 0.2–7.2) for the ICB + VEGFR group. For the IMDC intermediate-/poor-risk cohort, TFS was 2.1 mo (95% CI 1.4–2.8) for the VEGFR monotherapy group, 3.7 mo (95% CI 1.0–6.4) for the ICB + VEGFR group, and 5.3 mo (95% CI 3.8–6.8) for ICB doublet group. Limitations include the retrospective design and an inability to quantify time spent with adverse events.</div></div><div><h3>Conclusions and clinical implications</h3><div>Our study demonstrates that patients with IMDC intermediate or poor risk treated with ICB doublet therapy experienced longer TFS than those treated with VEGFR monotherapy in the first-line setting. These results emphasize the utility of TFS as an informative endpoint and provide survival estimates to inform decision-making in mRCC.</div></div><div><h3>Patient summary</h3><div>For patients with metastatic kidney cancer, we compared the survival time free from a second treatment line for different first-line treatment options. The results show that the time free from second-line treatment was longer when first-line treatment was with a combination of two immunotherapy drugs (ipilimumab and nivolumab) in comparison to other treatment options.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 171-178"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142914072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hall of Fame","authors":"","doi":"10.1016/S2588-9311(25)00034-3","DOIUrl":"10.1016/S2588-9311(25)00034-3","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Page viii"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143378739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital Twins in Urological Oncology: Precise Treatment Planning via Complex Modeling","authors":"Enrico Checcucci ,&nbsp;Christoph Oing ,&nbsp;Daniele Amparore ,&nbsp;Francesco Porpiglia ,&nbsp;Pasquale Rescigno","doi":"10.1016/j.euo.2024.10.005","DOIUrl":"10.1016/j.euo.2024.10.005","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 1-4"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria","authors":"Wei Shen Tan ,&nbsp;Amar Ahmad ,&nbsp;Yin Zhou ,&nbsp;Arjun Nathan ,&nbsp;Ayodeji Ogunbo ,&nbsp;Olayinka Gbolahan ,&nbsp;Neha Kallam ,&nbsp;Rebecca Smith ,&nbsp;Maen Khalifeh ,&nbsp;Wei Phin Tan ,&nbsp;Daniel Cohen ,&nbsp;Dimitrios Volanis ,&nbsp;Fiona M. Walter ,&nbsp;Peter Sasieni ,&nbsp;Ashish M. Kamat ,&nbsp;John D. Kelly","doi":"10.1016/j.euo.2024.05.005","DOIUrl":"10.1016/j.euo.2024.05.005","url":null,"abstract":"<div><h3>Background</h3><div>Hematuria is a cardinal symptom of urinary tract cancer and would require further investigations.</div></div><div><h3>Objective</h3><div>To determine the ability of renal bladder ultrasound (RBUS) with the Hematuria Cancer Risk Score (HCRS) to inform cystoscopy use in patients with hematuria.</div></div><div><h3>Design, setting, and participants</h3><div>The development cohort comprised 1984 patients with hematuria from 40 UK hospitals (DETECT 1; ClinicalTrials.gov: NCT02676180) who received RBUS. An independent validation cohort comprised 500 consecutive patients referred to secondary care for a suspicion of bladder cancer.</div></div><div><h3>Outcome measurements and statistical analysis</h3><div>Sensitivity and true negative of the HCRS and RBUS were assessed.</div></div><div><h3>Results and limitations</h3><div>A total of 134 (7%) and 36 (8%) patients in the development and validation cohorts, respectively, had a diagnosis of urinary tract cancer. Validation of the HCRS achieves good discrimination with an area under the receiver operating characteristic curve of 0.727 (95% confidence interval 0.648–0.800) in the validation cohort with sensitivity of 95% for the identification of cancer. Utilizing the cutoff of 4.500 derived from the HCRS in combination with RBUS in the development cohort, 680 (34%) patients would have been spared cystoscopy at the cost of missing a G1 Ta bladder cancer and a urinary tract cancer patient, while 117 (25%) patients would have avoided cystoscopy at the cost of missing a single patient of G1 Ta bladder cancer with sensitivity for the identification of cancer of 97% in the validation cohort.</div></div><div><h3>Conclusions</h3><div>The HCRS with RBUS offers good discriminatory ability in identifying patients who would benefit from cystoscopy, sparing selected patient cohorts from an invasive procedure.</div></div><div><h3>Patient summary</h3><div>The hematuria cancer risk score with renal bladder ultrasound allows for the triage of patients with hematuria who would benefit from visual examination of the bladder (cystoscopy). This resulted in 25% of patients safely omitting cystoscopy, which is an invasive procedure, and would lead to health care cost savings.</div></div>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":"8 1","pages":"Pages 87-93"},"PeriodicalIF":8.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}